Antiviral improved overall patient-reported measures of both upper, lower respiratory symptoms, shortened overall course of illness COLLEGE PARK, Ga., May 7, 2025 /PRNewswire/ -- Altesa BioSciences ...
-Proceeds to advance vapendavir, a first-in-class therapeutic for the treatment of rhinovirus, the predominant cause of respiratory exacerbations in millions with COPD and other chronic lung diseases- ...
Study will begin enrollment in Q1 2026 in the US and UK and leverage the BIOFIRE® SPOTFIRE® point-of-care diagnostics platform at U.S. sites ATLANTA and SALT LAKE CITY, Sept. 9, 2025 /PRNewswire/ -- ...
A doctor has outlined those who are most at risk of becoming ill with rhinovrius, which is a respiratory condition that develops in people as the common cold. Those with untreated asthma, COPD or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results